

EUROPEAN PATENT OFFICE
U.S. PATENT AND TRADEMARK OFFICE

CPC NOTICE OF CHANGES 1696

DATE: JANUARY 1, 2025

PROJECT RP12360

The following classification changes will be effected by this Notice of Changes:

<u>Action</u>	<u>Subclass</u>	<u>Group(s)</u>
SCHEME:		
Symbols Deleted:	A61K	39/46, 39/461, 39/4611, 39/4612, 39/4613, 39/4614, 39/4615, 39/462, 39/4621, 39/4622, 39/463, 39/4631, 39/4632, 39/4633, 39/4634, 39/4635, 39/4636, 39/4637, 39/464, 39/4641, 39/4642, 39/4643, 39/46431, 39/46432, 39/46433, 39/46434, 39/4644, 39/464401, 39/464402, 39/464403, 39/464404, 39/464406, 39/464407, 39/464408, 39/464409, 39/46441, 39/464411, 39/464412, 39/464413, 39/464414, 39/464416, 39/464417, 39/464418, 39/464419, 39/46442, 39/464421, 39/464422, 39/464424, 39/464426, 39/464428, 39/464429, 39/46443, 39/464431, 39/464432, 39/464433, 39/464434, 39/464435, 39/464436, 39/464438, 39/464439, 39/46444, 39/464441, 39/464442, 39/464444, 39/464448, 39/464449, 39/46445, 39/464451, 39/464452, 39/464453, 39/464454, 39/464456, 39/464457, 39/464458, 39/464459, 39/46446, 39/464461, 39/464462, 39/464463, 39/464464, 39/464466, 39/464468, 39/464469, 39/46447, 39/464471, 39/464472, 39/464473, 39/464474, 39/464476, 39/464478, 39/46448, 39/464481, 39/464482, 39/464484, 39/464486, 39/464488, 39/464489, 39/46449, 39/464491, 39/464492, 39/464493, 39/464494, 39/464495, 39/464496, 39/464497, 39/464498, 39/464499, 39/4645, 39/4646, 39/4647, 39/464711, 39/464712, 39/464713, 39/464714, 39/464715, 39/4648, 39/464811, 39/464812, 39/464813, 39/464814, 39/464815, 39/464816, 39/464817, 39/464818, 39/464819, 39/46482, 39/464821, 39/464822, 39/464823, 39/464824, 39/464825, 39/464826, 39/464827, 39/464828, 39/464829, 39/46483, 39/464831, 39/464832, 39/464833, 39/464834,

CPC NOTICE OF CHANGES 1696

DATE: JANUARY 1, 2025

PROJECT RP12360

<u>Action</u>	<u>Subclass</u>	<u>Group(s)</u>
		39/464835, 39/464838, 39/464839, 39/46484
	A61K	2239/26
Symbols New:	A61K	40/00, 40/10, 40/11, 40/13, 40/15, 40/17, 40/19, 40/20, 40/22, 40/24, 40/30, 40/31, 40/32, 40/33, 40/34, 40/35, 40/36, 40/40, 40/405, 40/41, 40/412, 40/414, 40/416, 40/418, 40/42, 40/4201, 40/4202, 40/4203, 40/4204, 40/4205, 40/4206, 40/4207, 40/4208, 40/4209, 40/421, 40/4211, 40/4212, 40/4213, 40/4214, 40/4215, 40/4216, 40/4217, 40/4218, 40/4219, 40/422, 40/4221, 40/4222, 40/4223, 40/4224, 40/4225, 40/4226, 40/4227, 40/4228, 40/4229, 40/423, 40/4231, 40/4232, 40/4233, 40/4234, 40/4235, 40/4236, 40/4237, 40/4238, 40/4239, 40/424, 40/4241, 40/4242, 40/4243, 40/4244, 40/4245, 40/4246, 40/4247, 40/4248, 40/4249, 40/425, 40/4251, 40/4252, 40/4253, 40/4254, 40/4255, 40/4256, 40/4257, 40/4258, 40/4259, 40/426, 40/4261, 40/4262, 40/4263, 40/4264, 40/4265, 40/4266, 40/4267, 40/4268, 40/4269, 40/427, 40/4271, 40/4272, 40/4273, 40/4274, 40/4275, 40/4276, 40/4277, 40/4278, 40/4279, 40/428, 40/4285, 40/429, 40/43, 40/432, 40/434, 40/436, 40/438, 40/4385, 40/44, 40/45, 40/4512, 40/4514, 40/4516, 40/4518, 40/452, 40/4522, 40/4524, 40/4526, 40/4528, 40/453, 40/4532, 40/4534, 40/4536, 40/4538, 40/454, 40/4542, 40/4544, 40/4546, 40/4548, 40/455, 40/456, 40/4562, 40/4564, 40/4566, 40/4568, 40/46, 40/48, 40/482, 40/50
Notes Deleted:	A61K	39/46
Note New:	A61K	40/00
DEFINITIONS:		
Definitions Deleted: (no frozen (F) symbol definitions should be deleted)	A61K	39/46
Definitions New:	A61K	40/00

The following subclasses/groups are also impacted by this Notice of Changes (indicate subclasses/groups outside of the project scope, such as those listed in the CRL): A61K 2239/00, C12N 5/00

CPC NOTICE OF CHANGES 1696

DATE: JANUARY 1, 2025

PROJECT RP12360

This Notice of Changes includes the following *[Check the ones included]:*

1. CLASSIFICATION SCHEME CHANGES

- A. New, Modified or Deleted Group(s)
- B. New, Modified or Deleted Warning(s)
- C. New, Modified or Deleted Note(s)
- D. New, Modified or Deleted Guidance Heading(s)

2. DEFINITIONS

- A. New or Modified Definitions (Full definition template)
- B. Modified or Deleted Definitions (Definitions Quick Fix)

3. REVISION CONCORDANCE LIST (RCL)

4. CHANGES TO THE CPC-TO-IPC CONCORDANCE LIST (CICL)

5. CHANGES TO THE CROSS-REFERENCE LIST (CRL)

CPC NOTICE OF CHANGES 1696

DATE: JANUARY 1, 2025

PROJECT RP12360

1. CLASSIFICATION SCHEME CHANGES

A. New, Modified or Deleted Group(s)

SUBCLASS A61K - PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES

Type*	Symbol	Indent Level Number of dots (e.g. 0, 1, 2)	Title “CPC only” text should normally be enclosed in {curly brackets}**	Transferred to[#]
D	A61K39/46	1	{Cellular immunotherapy}	<administrative transfer to A61K40/00>
D	A61K39/461	2	{characterised by the cell type used}	<administrative transfer to A61K40/10>
D	A61K39/4611	3	{T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]}	<administrative transfer to A61K40/11>
D	A61K39/4612	3	{B-cells}	<administrative transfer to A61K40/13>
D	A61K39/4613	3	{Natural-killer cells [NK or NK-T]}	<administrative transfer to A61K40/15>
D	A61K39/4614	3	{Monocytes; Macrophages}	<administrative transfer to A61K40/17>
D	A61K39/4615	3	{Dendritic cells}	<administrative transfer to A61K40/19>
D	A61K39/462	2	{characterized by the effect or the function of the cells}	<administrative transfer to A61K40/20>
D	A61K39/4621	3	{immunosuppressive or immunotolerising}	<administrative transfer to A61K40/22>
D	A61K39/4622	3	{Antigen presenting cells}	<administrative transfer to A61K40/24>

CPC NOTICE OF CHANGES 1696

DATE: JANUARY 1, 2025

PROJECT RP12360

D	A61K39/463	2	{characterised by recombinant expression}	<administrative transfer to A61K40/30>
D	A61K39/4631	3	{Chimeric Antigen Receptors [CAR]}	<administrative transfer to A61K40/31>
D	A61K39/4632	3	{T-cell receptors [TCR]; antibody T-cell receptor constructs}	<administrative transfer to A61K40/32>
D	A61K39/4633	3	{Antibodies or T cell engagers}	<administrative transfer to A61K40/33>
D	A61K39/4634	3	{Antigenic peptides; polypeptides}	<administrative transfer to A61K40/34>
D	A61K39/4635	3	{Cytokines}	<administrative transfer to A61K40/35>
D	A61K39/4636	3	{Immune checkpoint inhibitors}	<administrative transfer to A61K40/36>
D	A61K39/4637	3	{Other peptides or polypeptides}	<administrative transfer to A61K40/30>
D	A61K39/464	2	{characterised by the antigen targeted or presented}	<administrative transfer to A61K40/40>
D	A61K39/4641	3	{Fungal antigens, e.g. Trichophyton, Aspergillus or Candida}	<administrative transfer to A61K40/44>
D	A61K39/4642	3	{Invertebrate antigens}	<administrative transfer to A61K40/405>
D	A61K39/4643	3	{Vertebrate antigens}	<administrative transfer to A61K40/41>
D	A61K39/46431	4	{Contraceptive or sex hormones}	<administrative transfer to A61K40/412>
D	A61K39/46432	4	{Nervous system antigens}	<administrative transfer to A61K40/414>

CPC NOTICE OF CHANGES 1696

DATE: JANUARY 1, 2025

PROJECT RP12360

D	A61K39/46433	4	{Antigens related to a auto-immune diseases; Preparations to induce self-tolerance }	<administrative transfer to A61K40/416>
D	A61K39/46434	4	{Antigens related to induction of tolerance to non-self }	<administrative transfer to A61K40/418>
D	A61K39/4644	4	{Cancer antigens }	<administrative transfer to A61K40/42>
D	A61K39/464401	5	{Neoantigens }	<administrative transfer to A61K40/4201>
D	A61K39/464402	5	{Receptors, cell surface antigens or cell surface determinants }	<administrative transfer to A61K40/4202>
D	A61K39/464403	6	{Receptors for growth factors }	<administrative transfer to A61K40/4203>
D	A61K39/464404	7	{Epidermal growth factor receptors [EGFR]}	<administrative transfer to A61K40/4204>
D	A61K39/464406	7	{Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ ErbB4 }	<administrative transfer to A61K40/4205>
D	A61K39/464407	7	{Fibroblast growth factor receptors [FGFR]}	<administrative transfer to A61K40/4206>
D	A61K39/464408	7	{Platelet-derived growth factor receptors [PDGFR]}	<administrative transfer to A61K40/4207>
D	A61K39/464409	7	{Vascular endothelial growth factor receptors [VEGFR]}	<administrative transfer to A61K40/4208>
D	A61K39/46441	7	{Hepatocyte growth factor receptor [HGFR or c-met]}	<administrative transfer to A61K40/4209>
D	A61K39/464411	6	{Immunoglobulin superfamily }	<administrative transfer to A61K40/421>
D	A61K39/464412	7	{CD19 or B4 }	<administrative transfer to A61K40/4211>
D	A61K39/464413	7	{CD22, BL-CAM, siglec-2 or sialic acid binding Ig-related lectin 2 }	<administrative transfer to A61K40/4212>

CPC NOTICE OF CHANGES 1696

DATE: JANUARY 1, 2025

PROJECT RP12360

D	A61K39/464414	7	{CD74, Ii, MHC class II invariant chain or MHC class II gamma chain }	<administrative transfer to A61K40/4213>
D	A61K39/464416	6	{Receptors for cytokines }	<administrative transfer to A61K40/4214>
D	A61K39/464417	7	{Receptors for tumor necrosis factors [TNF], e.g. lymphotoxin receptor [LTR], CD30 }	<administrative transfer to A61K40/4215>
D	A61K39/464418	7	{Receptors for colony stimulating factors [CSF]}	<administrative transfer to A61K40/4216>
D	A61K39/464419	7	{Receptors for interleukins [IL]}	<administrative transfer to A61K40/4217>
D	A61K39/46442	7	{Receptors for interferons [IFN]}	<administrative transfer to A61K40/4218>
D	A61K39/464421	7	{Receptors for chemokines }	<administrative transfer to A61K40/4219>
D	A61K39/464422	6	{Ephrin Receptors [Eph]}	<administrative transfer to A61K40/422>
D	A61K39/464424	6	{CD20 }	<administrative transfer to A61K40/4221>
D	A61K39/464426	6	{CD38 not IgG }	<administrative transfer to A61K40/4222>
D	A61K39/464428	6	{CD44 not IgG }	<administrative transfer to A61K40/4223>
D	A61K39/464429	6	{Molecules with a "CD" designation not provided for elsewhere }	<administrative transfer to A61K40/4224>
D	A61K39/46443	5	{Growth factors }	<administrative transfer to A61K40/4225>
D	A61K39/464431	6	{Epidermal growth factor [EGF]}	<administrative transfer to A61K40/4226>
D	A61K39/464432	6	{Fibroblast growth factors [FGF]}	<administrative transfer to A61K40/4227>

CPC NOTICE OF CHANGES 1696

DATE: JANUARY 1, 2025

PROJECT RP12360

D	A61K39/464433	6	{Platelet-derived growth factor [PDGF]}	<administrative transfer to A61K40/4228>
D	A61K39/464434	6	{Transforming growth factor [TGF]}	<administrative transfer to A61K40/4229>
D	A61K39/464435	6	{Vascular endothelial growth factor [VEGF]}	<administrative transfer to A61K40/423>
D	A61K39/464436	5	{Cytokines}	<administrative transfer to A61K40/4231>
D	A61K39/464438	6	{Tumor necrosis factors [TNF], CD70}	<administrative transfer to A61K40/4232>
D	A61K39/464439	6	{Colony stimulating factors [CSF]}	<administrative transfer to A61K40/4233>
D	A61K39/46444	6	{Interleukins [IL]}	<administrative transfer to A61K40/4234>
D	A61K39/464441	6	{Interferons [IFN]}	<administrative transfer to A61K40/4235>
D	A61K39/464442	6	{Chemokines}	<administrative transfer to A61K40/4236>
D	A61K39/464444	5	{Hormones, e.g. calcitonin}	<administrative transfer to A61K40/4237>
D	A61K39/464448	5	{Regulators of development}	<administrative transfer to A61K40/4238>
D	A61K39/464449	6	{Cell cycle regulated proteins, e.g. cyclin, CDC, CDK or INK-CCR}	<administrative transfer to A61K40/4239>
D	A61K39/46445	6	{Apoptosis related proteins, e.g. survivin or livin}	<administrative transfer to A61K40/424>
D	A61K39/464451	7	{p53}	<administrative transfer to A61K40/4241>
D	A61K39/464452	5	{Transcription factors, e.g. SOX or c-MYC}	<administrative transfer to A61K40/4242>

CPC NOTICE OF CHANGES 1696

DATE: JANUARY 1, 2025

PROJECT RP12360

D	A61K39/464453	6	{Wilms tumor 1 [WT1]}	<administrative transfer to A61K40/4243>
D	A61K39/464454	5	{Enzymes}	<administrative transfer to A61K40/4244>
D	A61K39/464456	6	{Tyrosinase or tyrosinase related proteinases [TRP-1 or TRP-2]}	<administrative transfer to A61K40/4245>
D	A61K39/464457	6	{Telomerase or [telomerase reverse transcriptase [TERT]}	<administrative transfer to A61K40/4246>
D	A61K39/464458	6	{Proteinases}	<administrative transfer to A61K40/4247>
D	A61K39/464459	7	{Matrix metalloproteinases [MMP]}	<administrative transfer to A61K40/4248>
D	A61K39/46446	7	{Serine proteases, e.g. kallikrein}	<administrative transfer to A61K40/4249>
D	A61K39/464461	7	{Caspases}	<administrative transfer to A61K40/425>
D	A61K39/464462	6	{Kinases, e.g. Raf or Src}	<administrative transfer to A61K40/4251>
D	A61K39/464463	6	{Phosphatases}	<administrative transfer to A61K40/4252>
D	A61K39/464464	6	{GTPases, e.g. Ras or Rho}	<administrative transfer to A61K40/4253>
D	A61K39/464466	5	{Adhesion molecules, e.g. NRCAM, EpCAM or cadherins}	<administrative transfer to A61K40/4254>
D	A61K39/464468	6	{Mesothelin [MSLN]}	<administrative transfer to A61K40/4255>
D	A61K39/464469	5	{Tum or associated carbohydrates}	<administrative transfer to A61K40/4256>
D	A61K39/46447	6	{Mucins, e.g. MUC-1}	<administrative transfer to A61K40/4257>

CPC NOTICE OF CHANGES 1696

DATE: JANUARY 1, 2025

PROJECT RP12360

D	A61K39/464471	6	{Gangliosides, e.g. GM2, GD2 or GD3}	<administrative transfer to A61K40/4258>
D	A61K39/464472	6	{Sialyl-Thomson-nouvelle antigen [sTn]}	<administrative transfer to A61K40/4259>
D	A61K39/464473	6	{Globo-H}	<administrative transfer to A61K40/426>
D	A61K39/464474	5	{Proteoglycans, e.g. glypican, brevican or CSPG4}	<administrative transfer to A61K40/4261>
D	A61K39/464476	5	{Heat shock proteins}	<administrative transfer to A61K40/4262>
D	A61K39/464478	5	{Tumor rejection antigen precursor [TRAP]}	<administrative transfer to A61K40/4263>
D	A61K39/46448	5	{from embryonic or fetal origin}	<administrative transfer to A61K40/4264>
D	A61K39/464481	6	{Alpha-fetoprotein}	<administrative transfer to A61K40/4265>
D	A61K39/464482	6	{Carcinoembryonic antigen [CEA]}	<administrative transfer to A61K40/4266>
D	A61K39/464484	5	{Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE}	<administrative transfer to A61K40/4267>
D	A61K39/464486	6	{MAGE}	<administrative transfer to A61K40/4268>
D	A61K39/464488	6	{NY-ESO}	<administrative transfer to A61K40/4269>
D	A61K39/464489	6	{PRAME}	<administrative transfer to A61K40/427>
D	A61K39/46449	5	{Melanoma antigens}	<administrative transfer to A61K40/4271>
D	A61K39/464491	6	{Melan-A/MART}	<administrative transfer to A61K40/4272>

CPC NOTICE OF CHANGES 1696

DATE: JANUARY 1, 2025

PROJECT RP12360

D	A61K39/464492	6	{Glycoprotein 100[Gp100]}	<administrative transfer to A61K40/4273>
D	A61K39/464493	5	{Prostate associated antigens e.g. Prostate stem cell antigen [PSCA]; Prostate carcinoma tumor antigen [PCTA]; Prostatic acid phosphatase [PAP]; Prostate-specific G-protein-coupled receptor [PSGR]}	<administrative transfer to A61K40/4274>
D	A61K39/464494	6	{Prostate specific antigen [PSA]}	<administrative transfer to A61K40/4275>
D	A61K39/464495	6	{Prostate specific membrane antigen [PSMA]}	<administrative transfer to A61K40/4276>
D	A61K39/464496	5	{Fusion proteins originating from gene translocation in cancer cells}	<administrative transfer to A61K40/4277>
D	A61K39/464497	6	{Breakpoint cluster region-abelson tyrosine kinase [BCR-ABL]}	<administrative transfer to A61K40/4278>
D	A61K39/464498	6	{Pml-RARalpha}	<administrative transfer to A61K40/4279>
D	A61K39/464499	5	{Undefined tumor antigens, e.g. tumor lysate or antigens targeted by cells isolated from tumor}	<administrative transfer to A61K40/428>
D	A61K39/4645	4	{Lipids; Lipoproteins}	<administrative transfer to A61K40/4285>
D	A61K39/4646	3	{Small organic molecules e.g. cocaine or nicotine}	<administrative transfer to A61K40/429>
D	A61K39/4647	3	{Protozoa antigens}	<administrative transfer to A61K40/43>
D	A61K39/464711	4	{Trypanosoma antigens}	<administrative transfer to A61K40/432>
D	A61K39/464712	4	{Leishmania antigens}	<administrative transfer to A61K40/434>

CPC NOTICE OF CHANGES 1696

DATE: JANUARY 1, 2025

PROJECT RP12360

D	A61K39/464713	4	{Coccidia antigens}	<administrative transfer to A61K40/436>
D	A61K39/464714	4	{Hemosporidia antigens, e.g. Plasmodium antigens}	<administrative transfer to A61K40/438>
D	A61K39/464715	5	{Babesia antigens, e.g. Theileria antigens}	<administrative transfer to A61K40/4385>
D	A61K39/4648	3	{Bacterial antigens}	<administrative transfer to A61K40/45>
D	A61K39/464811	4	{Bacteroidetes, e.g. Bacteroides, Ornithobacter or Porphyromonas}	<administrative transfer to A61K40/4512>
D	A61K39/464812	4	{Spirochetes, e.g. Treponema, Leptospira or Borrelia}	<administrative transfer to A61K40/4514>
D	A61K39/464813	4	{Rickettsiales, e.g. Anaplasma}	<administrative transfer to A61K40/4516>
D	A61K39/464814	4	{Mollicutes, e.g. Mycoplasma or Erysipelothrix}	<administrative transfer to A61K40/4518>
D	A61K39/464815	4	{Enterobacteriales, e.g. Enterobacter}	<administrative transfer to A61K40/452>
D	A61K39/464816	5	{Yersinia}	<administrative transfer to A61K40/4522>
D	A61K39/464817	4	{Mycobacterium, e.g. Mycobacterium tuberculosis}	<administrative transfer to A61K40/4524>
D	A61K39/464818	4	{Corynebacterium or Propionibacterium, Actinobacteria, e.g. Actinomyces, Streptomyces, Nocardia, Bifidobacterium or Gardnerella}	<administrative transfer to A61K40/4526>
D	A61K39/464819	4	{Bacillus}	<administrative transfer to A61K40/4528>
D	A61K39/46482	4	{Clostridium, e.g. Clostridium tetani}	<administrative transfer to A61K40/453>
D	A61K39/464821	4	{Staphylococcus}	<administrative transfer to A61K40/4532>

CPC NOTICE OF CHANGES 1696

DATE: JANUARY 1, 2025

PROJECT RP12360

D	A61K39/464822	4	{Streptococcus}	<administrative transfer to A61K40/4534>
D	A61K39/464823	4	{Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus or lactococcus}	<administrative transfer to A61K40/4536>
D	A61K39/464824	4	{Neisseria}	<administrative transfer to A61K40/4538>
D	A61K39/464825	4	{Brucella; Bordetella, e.g. Bordetella pertussis}	<administrative transfer to A61K40/454>
D	A61K39/464826	4	{Pasteurellales, e.g. Actinobacillus, Pasteurella; Haemophilus}	<administrative transfer to A61K40/4542>
D	A61K39/464827	4	{Pseudomonadales, e.g. Pseudomonas}	<administrative transfer to A61K40/4544>
D	A61K39/464828	5	{Moraxella}	<administrative transfer to A61K40/4546>
D	A61K39/464829	4	{Delta proteobacteriales, e.g. Lawsonia; Epsilon proteobacteriales}	<administrative transfer to A61K40/4548>
D	A61K39/46483	4	{Vibrio; Campylobacter}	<administrative transfer to A61K40/455>
D	A61K39/464831	4	{Escherichia; Klebsiella}	<administrative transfer to A61K40/456>
D	A61K39/464832	4	{Salmonella; Shigella}	<administrative transfer to A61K40/4562>
D	A61K39/464833	4	{Fusobacterium}	<administrative transfer to A61K40/4564>

CPC NOTICE OF CHANGES 1696

DATE: JANUARY 1, 2025

PROJECT RP12360

D	A61K39/464834	4	{Polyvalent bacterial antigens}	<administrative transfer to A61K40/4566>
D	A61K39/464835	4	{Chlamydiaceae, e.g. Chlamydia trachomatis or Chlamydia psittaci}	<administrative transfer to A61K40/4568>
D	A61K39/464838	3	{Viral antigens}	<administrative transfer to A61K40/46>
D	A61K39/464839	3	{Allergens}	<administrative transfer to A61K40/48>
D	A61K39/46484	4	{from pollen}	<administrative transfer to A61K40/482>
U	A61K2039/892	2	{Reproductive system [uterus, ovaries, cervix, testes]}	
N	A61K40/00	0	Cellular immunotherapy (medicinal preparations containing antigens or antibodies A61K39/00)	
N	A61K40/10	1	characterised by the cell type used	
N	A61K40/11	2	T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells	
N	A61K40/13	2	B-cells	
N	A61K40/15	2	Natural-killer [NK] cells; Natural-killer T [NKT] cells	
N	A61K40/17	2	Monocytes; Macrophages	
N	A61K40/19	2	Dendritic cells	
N	A61K40/20	1	characterised by the effect or the function of the cells	
N	A61K40/22	2	Immunosuppressive or immunotolerising	
N	A61K40/24	2	Antigen-presenting cells [APC]	
N	A61K40/30	1	characterised by the recombinant expression of specific molecules in the cells of the immune system	
N	A61K40/31	2	Chimeric antigen receptors [CAR]	
N	A61K40/32	2	T-cell receptors [TCR]	

CPC NOTICE OF CHANGES 1696

DATE: JANUARY 1, 2025

PROJECT RP12360

N	A61K40/33	2	Antibodies; T-cell engagers	
N	A61K40/34	2	Antigenic peptides	
N	A61K40/35	2	Cytokines	
N	A61K40/36	2	Immune checkpoint inhibitors	
N	A61K40/40	1	characterised by antigens that are targeted or presented by cells of the immune system	
N	A61K40/405	2	{Invertebrates antigens}	
N	A61K40/41	2	Vertebrate antigens	
N	A61K40/412	3	{Contraceptive or sex hormones}	
N	A61K40/414	3	{Nervous system antigens}	
N	A61K40/416	3	{Antigens related to auto-immune diseases; Preparations to induce self-tolerance}	
N	A61K40/418	3	{Antigens related to induction of tolerance to non-self}	
N	A61K40/42	3	Cancer antigens	
N	A61K40/4201	4	{Neoantigens}	
N	A61K40/4202	4	{Receptors, cell surface antigens or cell surface determinants}	
N	A61K40/4203	5	{Receptors for growth factors}	
N	A61K40/4204	6	{Epidermal growth factor receptors [EGFR]}	
N	A61K40/4205	6	{Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ ErbB4}	
N	A61K40/4206	6	{Fibroblast growth factor receptors [FGFR]}	

CPC NOTICE OF CHANGES 1696

DATE: JANUARY 1, 2025

PROJECT RP12360

N	A61K40/4207	6	{Platelet-derived growth factor receptors [PDGFR]}	
N	A61K40/4208	6	{Vascular endothelial growth factor receptors [VEGFR]}	
N	A61K40/4209	6	{Hepatocyte growth factor receptor [HGFR] or c-met}	
N	A61K40/421	5	{Immunoglobulin superfamily }	
N	A61K40/4211	6	{CD19 or B4 }	
N	A61K40/4212	6	{CD22, BL-CAM, siglec-2 or sialic acid binding Ig-related lectin 2 }	
N	A61K40/4213	6	{CD74, Ii, MHC class II invariant chain or MHC class II gamma chain }	
N	A61K40/4214	5	{Receptors for cytokines }	
N	A61K40/4215	6	{Receptors for tumor necrosis factors [TNF], e.g. lymphotoxin receptor [LTR], CD30 }	
N	A61K40/4216	6	{Receptors for colony stimulating factors [CSF]}	
N	A61K40/4217	6	{Receptors for interleukins [IL]}	
N	A61K40/4218	6	{Receptors for interferons [IFN]}	
N	A61K40/4219	6	{Receptors for chemokines }	
N	A61K40/422	5	{Ephrin Receptors [Eph]}	
N	A61K40/4221	5	{CD20 }	

CPC NOTICE OF CHANGES 1696

DATE: JANUARY 1, 2025

PROJECT RP12360

N	A61K40/4222	5	{CD38 not IgG}	
N	A61K40/4223	5	{CD44 not IgG}	
N	A61K40/4224	5	{Molecules with a "CD" designation not provided for elsewhere}	
N	A61K40/4225	4	{Growth factors}	
N	A61K40/4226	5	{Epidermal growth factor [EGF]}	
N	A61K40/4227	5	{Fibroblast growth factors [FGF]}	
N	A61K40/4228	5	{Platelet-derived growth factor [PDGF]}	
N	A61K40/4229	5	{Transforming growth factor [TGF]}	
N	A61K40/423	5	{Vascular endothelial growth factor [VEGF]}	
N	A61K40/4231	4	{Cytokines}	
N	A61K40/4232	5	{Tumor necrosis factors [TNF] or CD70}	
N	A61K40/4233	5	{Colony stimulating factors [CSF]}	
N	A61K40/4234	5	{Interleukins [IL]}	
N	A61K40/4235	5	{Interferons [IFN]}	
N	A61K40/4236	5	{Chemokines}	

CPC NOTICE OF CHANGES 1696

DATE: JANUARY 1, 2025

PROJECT RP12360

N	A61K40/4237	4	{Hormones, e.g. calcitonin }	
N	A61K40/4238	4	{Regulators of development }	
N	A61K40/4239	5	{Cell cycle regulated proteins, e.g. cyclin, CDC, CDK or INK-CCR }	
N	A61K40/424	5	{Apoptosis related proteins, e.g. survivin or livin }	
N	A61K40/4241	6	{p53 }	
N	A61K40/4242	4	{Transcription factors, e.g. SOX or c-MYC }	
N	A61K40/4243	5	{Wilms tumor 1 [WT1]}	
N	A61K40/4244	4	{Enzymes }	
N	A61K40/4245	5	{Tyrosinase or tyrosinase related proteinases [TRP-1 or TRP-2]}	
N	A61K40/4246	5	{Telomerase or [telomerase reverse transcriptase [TERT]}	
N	A61K40/4247	5	{Proteinases }	
N	A61K40/4248	6	{Matrix metalloproteinases [MMP]}	
N	A61K40/4249	6	{Serine proteases, e.g. kallikrein }	
N	A61K40/425	6	{Caspases }	
N	A61K40/4251	5	{Kinases, e.g. Raf or Src }	

CPC NOTICE OF CHANGES 1696

DATE: JANUARY 1, 2025

PROJECT RP12360

N	A61K40/4252	5	{Phosphatases}	
N	A61K40/4253	5	{GTPases, e.g. Ras or Rho}	
N	A61K40/4254	4	{Adhesion molecules, e.g. NRCAM, EpCAM or cadherins}	
N	A61K40/4255	5	{Mesothelin [MSLN]}	
N	A61K40/4256	4	{Tum or associated carbohydrates}	
N	A61K40/4257	5	{Mucins, e.g. MUC-1}	
N	A61K40/4258	5	{Gangliosides, e.g. GM2, GD2 or GD3}	
N	A61K40/4259	5	{Sialyl-Thomson-nouvelle antigen [sTn]}	
N	A61K40/426	5	{Globo-H}	
N	A61K40/4261	4	{Proteoglycans, e.g. glypican, brevican or CSPG4}	
N	A61K40/4262	4	{Heat shock proteins}	
N	A61K40/4263	4	{Tum or rejection antigen precursor [TRAP]}	
N	A61K40/4264	4	{from embryonic or fetal origin}	
N	A61K40/4265	5	{Alpha-feto protein}	
N	A61K40/4266	5	{Carcinoembryonic antigen [CEA]}	

CPC NOTICE OF CHANGES 1696

DATE: JANUARY 1, 2025

PROJECT RP12360

N	A61K40/4267	4	{Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE}	
N	A61K40/4268	5	{MAGE}	
N	A61K40/4269	5	{NY-ESO}	
N	A61K40/427	5	{PRAME}	
N	A61K40/4271	4	{Melanoma antigens}	
N	A61K40/4272	5	{Melan-A/MART}	
N	A61K40/4273	5	{Glycoprotein 100 [Gp100]}	
N	A61K40/4274	4	{Prostate associated antigens e.g. Prostate stem cell antigen [PSCA]; Prostate carcinoma tumor antigen [PCTA]; Prostatic acid phosphatase [PAP]; Prostate-specific G-protein-coupled receptor [PSGR]}	
N	A61K40/4275	5	{Prostate specific antigen [PSA]}	
N	A61K40/4276	5	{Prostate specific membrane antigen [PSMA]}	
N	A61K40/4277	4	{Fusion proteins originating from gene translocation in cancer cells}	
N	A61K40/4278	5	{Breakpoint cluster region-abelson tyrosine kinase [BCR-ABL]}	
N	A61K40/4279	5	{Pml-RARalpha}	
N	A61K40/428	4	{Undefined tumor antigens, e.g. tumor lysate or antigens targeted by cells isolated from tumor}	

CPC NOTICE OF CHANGES 1696

DATE: JANUARY 1, 2025

PROJECT RP12360

N	A61K40/4285	3	{Lipids; Lipoproteins}	
N	A61K40/429	2	{Small organic molecules e.g. cocaine or nicotine}	
N	A61K40/43	2	Protozoan antigens	
N	A61K40/432	3	{Trypanosoma antigens}	
N	A61K40/434	3	{Leishmania antigens}	
N	A61K40/436	3	{Coccidia antigens}	
N	A61K40/438	3	{Hemosporidia antigens, e.g. Plasmodium antigens}	
N	A61K40/4385	4	{Babesia antigens, e.g. Theileria antigens}	
N	A61K40/44	2	Fungal antigens	
N	A61K40/45	2	Bacterial antigens	
N	A61K40/4512	3	{Bacteroidetes, e.g. Bacteroides, Ornithobacter or Porphyromonas}	
N	A61K40/4514	3	{Spirochetes, e.g. Treponema, Leptospira or Borrelia}	
N	A61K40/4516	3	{Rickettsiales, e.g. Anaplasma}	
N	A61K40/4518	3	{Mollicutes, e.g. Mycoplasma or Erysipelothrix}	
N	A61K40/452	3	{Enterobacteriales, e.g. Enterobacter}	
N	A61K40/4522	4	{Yersinia}	

CPC NOTICE OF CHANGES 1696

DATE: JANUARY 1, 2025

PROJECT RP12360

N	A61K40/4524	3	{Mycobacterium, e.g. Mycobacterium tuberculosis }	
N	A61K40/4526	3	{Corynebacterium or Propionibacterium, Actinobacteria, e.g. Actinomyces, Streptomyces, Nocardia, Bifidobacterium or Gardnerella }	
N	A61K40/4528	3	{Bacillus }	
N	A61K40/453	3	{Clostridium, e.g. Clostridium tetani }	
N	A61K40/4532	3	{Staphylococcus }	
N	A61K40/4534	3	{Streptococcus }	
N	A61K40/4536	3	{Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus or lactococcus }	
N	A61K40/4538	3	{Neisseria }	
N	A61K40/454	3	{Brucella; Bordetella, e.g. Bordetella pertussis }	
N	A61K40/4542	3	{Pasteurellales, e.g. Actinobacillus, Pasteurella; Haemophilus }	
N	A61K40/4544	3	{Pseudomonadales, e.g. Pseudomonas }	
N	A61K40/4546	4	{Moraxella }	
N	A61K40/4548	3	{Delta proteobacteriales, e.g. Lawsonia; Epsilon proteobacteriales }	

CPC NOTICE OF CHANGES 1696

DATE: JANUARY 1, 2025

PROJECT RP12360

N	A61K40/455	3	{Vibrio; Campylobacter}	
N	A61K40/456	3	{Escherichia; Klebsiella}	
N	A61K40/4562	3	{Salmonella; Shigella}	
N	A61K40/4564	3	{Fusobacterium}	
N	A61K40/4566	3	{Polyvalent bacterial antigens}	
N	A61K40/4568	3	{Chlamydiaceae, e.g. Chlamydia trachomatis or Chlamydia psittaci}	
N	A61K40/46	2	Viral antigens	
N	A61K40/48	2	Allergens	
N	A61K40/482	3	{from pollen}	
N	A61K40/50	1	characterised by the use of allogeneic cells	
D	A61K2239/26	1	Universal/off- the- shelf cellular immunotherapy; Allogenic cells or means to avoid rejection	<administrative transfer to A61K40/50>

*N = new entries where reclassification into entries is involved; C = entries with modified file scope where reclassification of documents from the entries is involved; Q = new entries which are firstly populated with documents via administrative transfers from deleted (D) entries. Afterwards, the transferred documents into the Q entry will either stay or be moved to more appropriate entries, as determined by intellectual reclassification; T = existing entries with enlarged file scope, which receive documents from C or D entries, e.g. when a limiting reference is removed from the entry title; M = entries with no change to the file scope (no reclassification); D = deleted entries; F = frozen entries will be deleted once reclassification of documents from the entries is completed; U = entries that are unchanged.

NOTES:

CPC NOTICE OF CHANGES 1696

DATE: JANUARY 1, 2025

PROJECT RP12360

- **No {curly brackets } are used for titles in CPC only subclasses, e.g. C12Y, A23Y; 2000 series symbol titles of groups found at the end of schemes (orthogonal codes); or the Y section titles. The {curly brackets } are used for 2000 series symbol titles found interspersed throughout the main trunk schemes (breakdown codes).
- U groups: it is obligatory to display the required “anchor” symbol (U group), i.e. the entry immediately preceding a new group or an array of new groups to be created (in case new groups are not clearly subgroups of C-type groups). Always include the symbol, indent level and title of the U group in the table above.
- All entry types should be included in the scheme changes table above for better understanding of the overall scheme change picture. Symbol, indent level, and title are required for all types.
- “Transferred to” column must be completed for all C, D, F, and Q type entries. F groups will be deleted once reclassification is completed.
- When multiple symbols are included in the “Transferred to” column, avoid using ranges of symbols in order to be as precise as possible.
- For administrative transfer of documents, the following text should be used: “<administrative transfer to XX>”, “<administrative transfer to XX and YY simultaneously>”, or “<administrative transfer to XX, YY, ...and ZZ simultaneously>” when administrative transfer of the same documents is to more than one place.
- Administrative transfer to main trunk groups is assumed to be the source allocation type, unless otherwise indicated.
- Administrative transfer to 2000/Y series groups is assumed to be “additional information”.
- If needed, instructions for allocation type should be indicated within the angle brackets using the abbreviations “ADD” or “INV”: <administrative transfer to XX ADD>, <administrative transfer to XX INV>, or <administrative transfer to XX ADD, YY INV, ... and ZZ ADD simultaneously>.
- In certain situations, the “D” entries of 2000-series or Y-series groups may not require a destination (“Transferred to”) symbol, however it is required to specify “<no transfer>” in the “Transferred to” column for such cases.
- For finalization projects, the deleted “F” symbols should have <no transfer> in the “Transferred to” column.
- For more details about the types of scheme change, see CPC Guide.

CPC NOTICE OF CHANGES 1696

DATE: JANUARY 1, 2025

PROJECT RP12360

C. New, Modified or Deleted Note(s)

SUBCLASS A61K - PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES

Type*	Location	Old Note	New/Modified Note
D	A61K39/46	In this group, C-Sets are used for classification. The detailed information about the C-Sets construction and the associated syntax rules are found in the Definitions of A61K39/46.	Delete entire Note
N	A61K40/00		In this group, C-Sets are used for classification. The detailed information about the C-Sets construction and the associated syntax rules are found in the Definitions of A61K40/00.

*N = new note, M = modified note, D = deleted note

NOTE: The "Location" column only requires the symbol PRIOR to the location of the note. No further directions such as "before" or "after" are required.

2. A. DEFINITIONS (new)

A61K 40/00

Definition statement

This place covers:

Isolated cells of the immune system presenting or targeting a specific antigen or a mix of antigens for use in therapy against, e.g. cancer, infectious diseases or auto-immune diseases.

The antigen presented/targeted may be a single epitope or a mix of epitopes or antigens.

Antigens may also be undefined like in the case of TILs or LAKs derived lymphocytes which will target several unidentified antigens.

Relationships with other classification places

Due to their structure, cells used in cellular immunotherapy may warrant classification of subject-matter in various main groups, beyond the allocation in [A61K 40/00](#) and subgroups.

If the structure of the antibody portion of the construct is an important aspect, then classification in [C07K 16/00](#) and subgroups should be considered. The same applies to the type of protein expressed (TCR, CAR, cytokine...), which can be classified in [C07K 14/00](#) and subgroups.

Genetically modified cells or T lymphocytes for immunotherapy may be classified in [C12N 5/0634](#) - [C12N 5/064](#) with added classification in [A61K 40/00](#) and subgroups, and indexing codes [A61K 2239/00](#) - [A61K 2239/59](#). Documents relating to the in vitro cell culture/expansion methods or to specific types/subtypes of immune cells may also be classified in [C12N 5/00](#) and subgroups.

Cells for cellular immunotherapy may be given symbols in [A61K 35/15](#) (e.g. dendritic cells) and/or [A61K 35/17](#) (e.g. lymphocytes; B-cells; T-cells; natural killer cells; interferon-activated or cytokine-activated lymphocytes) for the cell and [A61K 39/00](#) and subgroups for the therapeutic aspect of the antigen/antibody, as well as in [C07K 14/00](#) (when a novel peptide is claimed and exemplified) and/or [C07K 16/00](#) and subgroups (for further, specific classification of the antibody and/or when the antibody is novel).

DATE: JANUARY 1, 2025

PROJECT RP12360

Classification in [A61K 35/17](#) should be considered if the effect of the lymphocyte is not due to its antigen specificity (e.g. the administration of B cells to treat tissue injury). [A61K 35/15](#) or [A61K 35/17](#) need not be given by default to immune cells directed to a given antigen (or to a mixture of antigens).

Therapeutic activity can further be classified in subclass [A61P](#), as secondary classification and following the criteria outlined in the definitions of [A61P](#).

References

Limiting references

This place does not cover:

Medicinal preparations containing antigens or antibodies	A61K 39/00
--	----------------------------

Informative references

Attention is drawn to the following places, which may be of interest for search:

Medicinal preparations containing blood or cells from blood	A61K 35/17
Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy	A61K 48/00
T-cell receptor (TcR)-CD3 complex	C07K 14/7051
Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies	C07K 16/00
Fusion polypeptide (containing a transmembrane segment)	C07K 2319/00
Culture or maintenance of cells from the blood or the immune system	C12N 5/0634
Screening and/or testing using cells	C12Q 1/00

DATE: JANUARY 1, 2025

PROJECT RP12360

Special rules of classification

In this group, classification of the cell type and of the antigen specificity is compulsory, provided the document contains credible evidence that the effect has been or can be achieved.

Further relevant aspects, like those characterising the structure of the chimeric antigen receptor [CAR], the target(s) and the route of administration, should also be classified.

The cell type and the type of immune response is to be classified in subgroups [A61K 40/10](#) - [A61K 40/24](#).

These subgroups relate to immune cells, including antigen-presenting cells or T lymphocytes. Further aspects relate to the type of immune responses, which can be for instance, immunosuppressive or immunostimulatory ([A61K 40/20](#) - [A61K 40/24](#)).

Aspects relating to the nature of the receptors or molecules expressed recombinantly by the immune cell are to be classified in subgroups [A61K 40/30](#) - [A61K 40/36](#). CAR receptors are for instance, classified in [A61K 40/31](#).

The former subgroups should all be used in combination with the subgroups relating to the target antigen(s), which are to be found in subgroups [A61K 40/40](#) - [A61K 40/482](#).

The additional subgroups [A61K 2239/00](#) - [A61K 2239/59](#) should also be considered for a comprehensive classification of cellular immunotherapy.

These subgroups concern the structure of the chimeric antigen receptor [CAR], as well as the mechanisms enabling the control of the function or activity of the CAR or of the CAR-expressing cells in vivo.

In case of multiple targets, classification in the subgroups [A61K 2239/27](#) - [A61K 2239/30](#) can also be considered.

The route of administration, the schedule and the adjuvant(s) used can be classified in [A61K 2239/31](#) - [A61K 2239/39](#).

Finally, and in view of the wide use of cellular immunotherapy against cancer, specific subgroups for the cancer organ can be found in subgroups [A61K 2239/46](#) - [A61K 2239/59](#). These subgroups can be used in combination with the antigen subgroups to more precisely identify documents relating to some specific cancers.

Combination Sets (C-Sets) classification:

CPC NOTICE OF CHANGES 1696

DATE: JANUARY 1, 2025

PROJECT RP12360

- In groups [A61K 40/00](#) - [A61K 40/482](#), the combined use of cellular immunotherapy with other therapeutic elements classified in [A61K 31/00](#) - [A61K 41/00](#) are classified in the form of C-Sets.
- While multiple drugs are used in an invention, only the essential components of the invention that differentiate them from the prior art are given C-Sets.

C-Sets syntax rules:

- Each C-Set shall contain exactly two symbols, in which the base symbol represents one therapeutic drug belonging to [A61K 31/00](#) - [A61K 41/00](#), and followed by a subsequent symbol of [A61K 2300/00](#).
- Two or more separate C-Sets are made when two or more drugs are used in combination with cellular immunotherapy. See examples below.

C-Sets examples:

- Example 1: The treatment of blood cancer with anti-CD19 CAR-T cells and venetoclax is classified as ([A61K 40/4211](#), [A61K 2300/00](#)).
- Example 2: The treatment of blood cancer with anti-CD19 CAR-T cells and exogenous IL-7 is classified as ([A61K 40/4211](#), [A61K 2300/00](#)).
- Example 3: The treatment of cancer with anti-CEA CAR-T cells combined with anti-PD-L1 antibodies is classified as ([A61K 40/4266](#), [A61K 2300/00](#)).

CPC NOTICE OF CHANGES 1696

DATE: JANUARY 1, 2025

PROJECT RP12360

2. B. DEFINITIONS QUICK FIX

Symbol	Location of change (e.g., section title)	Existing reference symbol or text	Action; New symbol; New text
D	A61K39/46		Delete entire Definition

Notes:

Use this Definitions Quick Fix (DQF) table to:

- Delete an entire definition
- Delete an entire section
- Change a reference symbol
- Delete a reference symbol
- Delete text in a References section
- Correct one error in spelling, article use, or verb tense

Otherwise, use the standard template.

Reminder: Never delete F symbol definitions.

CPC NOTICE OF CHANGES 1696

DATE: JANUARY 1, 2025

PROJECT RP12360

3. REVISION CONCORDANCE LIST (RCL)

Type*	From CPC Symbol (existing)	To CPC Symbol(s)
D	A61K 39/46	<administrative transfer to A61K 40/00>
D	A61K 39/461	<administrative transfer to A61K 40/10>
D	A61K 39/4611	<administrative transfer to A61K 40/11>
D	A61K 39/4612	<administrative transfer to A61K 40/13>
D	A61K 39/4613	<administrative transfer to A61K 40/15>
D	A61K 39/4614	<administrative transfer to A61K 40/17>
D	A61K 39/4615	<administrative transfer to A61K 40/19>
D	A61K 39/462	<administrative transfer to A61K 40/20>
D	A61K 39/4621	<administrative transfer to A61K 40/22>
D	A61K 39/4622	<administrative transfer to A61K 40/24>
D	A61K 39/463	<administrative transfer to A61K 40/30>
D	A61K 39/4631	<administrative transfer to A61K 40/31>
D	A61K 39/4632	<administrative transfer to A61K 40/32>
D	A61K 39/4633	<administrative transfer to A61K 40/33>
D	A61K 39/4634	<administrative transfer to A61K 40/34>
D	A61K 39/4635	<administrative transfer to A61K 40/35>
D	A61K 39/4636	<administrative transfer to A61K 40/36>
D	A61K 39/4637	<administrative transfer to A61K 40/30>
D	A61K 39/464	<administrative transfer to A61K 40/40>
D	A61K 39/4641	<administrative transfer to A61K 40/44>
D	A61K 39/4642	<administrative transfer to A61K 40/405>
D	A61K 39/4643	<administrative transfer to A61K 40/41>
D	A61K 39/46431	<administrative transfer to A61K 40/412>
D	A61K 39/46432	<administrative transfer to A61K 40/414>
D	A61K 39/46433	<administrative transfer to A61K 40/416>
D	A61K 39/46434	<administrative transfer to A61K 40/418>
D	A61K 39/4644	<administrative transfer to A61K 40/42>
D	A61K 39/464401	<administrative transfer to A61K 40/4201>
D	A61K 39/464402	<administrative transfer to A61K 40/4202>
D	A61K 39/464403	<administrative transfer to A61K 40/4203>
D	A61K 39/464404	<administrative transfer to A61K 40/4204>
D	A61K 39/464406	<administrative transfer to A61K 40/4205>
D	A61K 39/464407	<administrative transfer to A61K 40/4206>
D	A61K 39/464408	<administrative transfer to A61K 40/4207>
D	A61K 39/464409	<administrative transfer to A61K 40/4208>
D	A61K 39/46441	<administrative transfer to A61K 40/4209>
D	A61K 39/464411	<administrative transfer to A61K 40/421>
D	A61K 39/464412	<administrative transfer to A61K 40/4211>
D	A61K 39/464413	<administrative transfer to A61K 40/4212>
D	A61K 39/464414	<administrative transfer to A61K 40/4213>
D	A61K 39/464416	<administrative transfer to A61K 40/4214>
D	A61K 39/464417	<administrative transfer to A61K 40/4215>
D	A61K 39/464418	<administrative transfer to A61K 40/4216>
D	A61K 39/464419	<administrative transfer to A61K 40/4217>
D	A61K 39/46442	<administrative transfer to A61K 40/4218>
D	A61K 39/464421	<administrative transfer to A61K 40/4219>

CPC NOTICE OF CHANGES 1696

DATE: JANUARY 1, 2025

PROJECT RP12360

Type*	<u>From CPC Symbol (existing)</u>	<u>To CPC Symbol(s)</u>
D	A61K 39/464422	<administrative transfer to A61K 40/422>
D	A61K 39/464424	<administrative transfer to A61K 40/4221>
D	A61K 39/464426	<administrative transfer to A61K 40/4222>
D	A61K 39/464428	<administrative transfer to A61K 40/4223>
D	A61K 39/464429	<administrative transfer to A61K 40/4224>
D	A61K 39/46443	<administrative transfer to A61K 40/4225>
D	A61K 39/464431	<administrative transfer to A61K 40/4226>
D	A61K 39/464432	<administrative transfer to A61K 40/4227>
D	A61K 39/464433	<administrative transfer to A61K 40/4228>
D	A61K 39/464434	<administrative transfer to A61K 40/4229>
D	A61K 39/464435	<administrative transfer to A61K 40/423>
D	A61K 39/464436	<administrative transfer to A61K 40/4231>
D	A61K 39/464438	<administrative transfer to A61K 40/4232>
D	A61K 39/464439	<administrative transfer to A61K 40/4233>
D	A61K 39/46444	<administrative transfer to A61K 40/4234>
D	A61K 39/464441	<administrative transfer to A61K 40/4235>
D	A61K 39/464442	<administrative transfer to A61K 40/4236>
D	A61K 39/464444	<administrative transfer to A61K 40/4237>
D	A61K 39/464448	<administrative transfer to A61K 40/4238>
D	A61K 39/464449	<administrative transfer to A61K 40/4239>
D	A61K 39/46445	<administrative transfer to A61K 40/424>
D	A61K 39/464451	<administrative transfer to A61K 40/4241>
D	A61K 39/464452	<administrative transfer to A61K 40/4242>
D	A61K 39/464453	<administrative transfer to A61K 40/4243>
D	A61K 39/464454	<administrative transfer to A61K 40/4244>
D	A61K 39/464456	<administrative transfer to A61K 40/4245>
D	A61K 39/464457	<administrative transfer to A61K 40/4246>
D	A61K 39/464458	<administrative transfer to A61K 40/4247>
D	A61K 39/464459	<administrative transfer to A61K 40/4248>
D	A61K 39/46446	<administrative transfer to A61K 40/4249>
D	A61K 39/464461	<administrative transfer to A61K 40/425>
D	A61K 39/464462	<administrative transfer to A61K 40/4251>
D	A61K 39/464463	<administrative transfer to A61K 40/4252>
D	A61K 39/464464	<administrative transfer to A61K 40/4253>
D	A61K 39/464466	<administrative transfer to A61K 40/4254>
D	A61K 39/464468	<administrative transfer to A61K 40/4255>
D	A61K 39/464469	<administrative transfer to A61K 40/4256>
D	A61K 39/46447	<administrative transfer to A61K 40/4257>
D	A61K 39/464471	<administrative transfer to A61K 40/4258>
D	A61K 39/464472	<administrative transfer to A61K 40/4259>
D	A61K 39/464473	<administrative transfer to A61K 40/426>
D	A61K 39/464474	<administrative transfer to A61K 40/4261>
D	A61K 39/464476	<administrative transfer to A61K 40/4262>
D	A61K 39/464478	<administrative transfer to A61K 40/4263>
D	A61K 39/46448	<administrative transfer to A61K 40/4264>
D	A61K 39/464481	<administrative transfer to A61K 40/4265>
D	A61K 39/464482	<administrative transfer to A61K 40/4266>
D	A61K 39/464484	<administrative transfer to A61K 40/4267>
D	A61K 39/464486	<administrative transfer to A61K 40/4268>
D	A61K 39/464488	<administrative transfer to A61K 40/4269>

CPC NOTICE OF CHANGES 1696

DATE: JANUARY 1, 2025

PROJECT RP12360

Type*	From CPC Symbol (existing)	To CPC Symbol(s)
D	A61K 39/464489	<administrative transfer to A61K 40/427>
D	A61K 39/46449	<administrative transfer to A61K 40/4271>
D	A61K 39/464491	<administrative transfer to A61K 40/4272>
D	A61K 39/464492	<administrative transfer to A61K 40/4273>
D	A61K 39/464493	<administrative transfer to A61K 40/4274>
D	A61K 39/464494	<administrative transfer to A61K 40/4275>
D	A61K 39/464495	<administrative transfer to A61K 40/4276>
D	A61K 39/464496	<administrative transfer to A61K 40/4277>
D	A61K 39/464497	<administrative transfer to A61K 40/4278>
D	A61K 39/464498	<administrative transfer to A61K 40/4279>
D	A61K 39/464499	<administrative transfer to A61K 40/428>
D	A61K 39/4645	<administrative transfer to A61K 40/4285>
D	A61K 39/4646	<administrative transfer to A61K 40/429>
D	A61K 39/4647	<administrative transfer to A61K 40/43>
D	A61K 39/464711	<administrative transfer to A61K 40/432>
D	A61K 39/464712	<administrative transfer to A61K 40/434>
D	A61K 39/464713	<administrative transfer to A61K 40/436>
D	A61K 39/464714	<administrative transfer to A61K 40/438>
D	A61K 39/464715	<administrative transfer to A61K 40/4385>
D	A61K 39/4648	<administrative transfer to A61K 40/45>
D	A61K 39/464811	<administrative transfer to A61K 40/4512>
D	A61K 39/464812	<administrative transfer to A61K 40/4514>
D	A61K 39/464813	<administrative transfer to A61K 40/4516>
D	A61K 39/464814	<administrative transfer to A61K 40/4518>
D	A61K 39/464815	<administrative transfer to A61K 40/452>
D	A61K 39/464816	<administrative transfer to A61K 40/4522>
D	A61K 39/464817	<administrative transfer to A61K 40/4524>
D	A61K 39/464818	<administrative transfer to A61K 40/4526>
D	A61K 39/464819	<administrative transfer to A61K 40/4528>
D	A61K 39/46482	<administrative transfer to A61K 40/453>
D	A61K 39/464821	<administrative transfer to A61K 40/4532>
D	A61K 39/464822	<administrative transfer to A61K 40/4534>
D	A61K 39/464823	<administrative transfer to A61K 40/4536>
D	A61K 39/464824	<administrative transfer to A61K 40/4538>
D	A61K 39/464825	<administrative transfer to A61K 40/454>
D	A61K 39/464826	<administrative transfer to A61K 40/4542>
D	A61K 39/464827	<administrative transfer to A61K 40/4544>
D	A61K 39/464828	<administrative transfer to A61K 40/4546>
D	A61K 39/464829	<administrative transfer to A61K 40/4548>
D	A61K 39/46483	<administrative transfer to A61K 40/455>
D	A61K 39/464831	<administrative transfer to A61K 40/456>
D	A61K 39/464832	<administrative transfer to A61K 40/4562>
D	A61K 39/464833	<administrative transfer to A61K 40/4564>
D	A61K 39/464834	<administrative transfer to A61K 40/4566>
D	A61K 39/464835	<administrative transfer to A61K 40/4568>
D	A61K 39/464838	<administrative transfer to A61K 40/46>
D	A61K 39/464839	<administrative transfer to A61K 40/48>
D	A61K 39/46484	<administrative transfer to A61K 40/482>
D	A61K 2239/26	<administrative transfer to A61K 40/50>

CPC NOTICE OF CHANGES 1696

DATE: JANUARY 1, 2025

PROJECT RP12360

* C = entries with modified file scope where reclassification of documents from the entries is involved; Q = new entries which are firstly populated with documents via administrative transfers from deleted (D) entries. Afterwards, the transferred documents into the Q entry will either stay or be moved to more appropriate entries, as determined by intellectual reclassification; D = deleted entries; F = frozen entries will be deleted once reclassification of documents from the entries is completed.

NOTES:

- Only C, D, F, and Q type entries are included in the table above.
- When multiple symbols are included in the “To” column, do not use ranges of symbols.
- For administrative transfer of documents, the following text should be used: “< administrative transfer to XX>”, “<administrative transfer to XX and YY simultaneously>”, or “<administrative transfer to XX, YY, ...and ZZ simultaneously>” when administrative transfer of the same documents is to more than one place.
- Administrative transfer to main trunk groups is assumed to be the source allocation type, unless otherwise indicated.
- Administrative transfer to 2000/Y series groups is assumed to be “additional information”.
- If needed, instructions for allocation type should be indicated within the angle brackets using the abbreviations “ADD” or “INV”: <administrative transfer to XX ADD>, <administrative transfer to XX INV>, or < administrative transfer to XX ADD, YY INV, ... and ZZ ADD simultaneously>.
- In certain situations, the “D” entries of 2000-series or Y-series groups may not require a destination (“To”)symbol, however it is required to specify “<no transfer>” in the “To” column for such cases.
- RCL is not needed for finalisation projects.

CPC NOTICE OF CHANGES 1696

DATE: JANUARY 1, 2025

PROJECT RP12360

4. CHANGES TO THE CPC-TO-IPC CONCORDANCE LIST (CICL)

CPC	IPC	Action*
A61K 39/46		DELETE
A61K 39/461		DELETE
A61K 39/4611		DELETE
A61K 39/4612		DELETE
A61K 39/4613		DELETE
A61K 39/4614		DELETE
A61K 39/4615		DELETE
A61K 39/462		DELETE
A61K 39/4621		DELETE
A61K 39/4622		DELETE
A61K 39/463		DELETE
A61K 39/4631		DELETE
A61K 39/4632		DELETE
A61K 39/4633		DELETE
A61K 39/4634		DELETE
A61K 39/4635		DELETE
A61K 39/4636		DELETE
A61K 39/4637		DELETE
A61K 39/464		DELETE
A61K 39/4641		DELETE
A61K 39/4642		DELETE
A61K 39/4643		DELETE
A61K 39/46431		DELETE
A61K 39/46432		DELETE
A61K 39/46433		DELETE
A61K 39/46434		DELETE
A61K 39/4644		DELETE
A61K 39/464401		DELETE
A61K 39/464402		DELETE
A61K 39/464403		DELETE
A61K 39/464404		DELETE
A61K 39/464406		DELETE
A61K 39/464407		DELETE
A61K 39/464408		DELETE
A61K 39/464409		DELETE
A61K 39/46441		DELETE
A61K 39/464411		DELETE
A61K 39/464412		DELETE
A61K 39/464413		DELETE
A61K 39/464414		DELETE
A61K 39/464416		DELETE

CPC NOTICE OF CHANGES 1696

DATE: JANUARY 1, 2025

PROJECT RP12360

<u>CPC</u>	<u>IPC</u>	<u>Action*</u>
A61K 39/464417		DELETE
A61K 39/464418		DELETE
A61K 39/464419		DELETE
A61K 39/46442		DELETE
A61K 39/464421		DELETE
A61K 39/464422		DELETE
A61K 39/464424		DELETE
A61K 39/464426		DELETE
A61K 39/464428		DELETE
A61K 39/464429		DELETE
A61K 39/46443		DELETE
A61K 39/464431		DELETE
A61K 39/464432		DELETE
A61K 39/464433		DELETE
A61K 39/464434		DELETE
A61K 39/464435		DELETE
A61K 39/464436		DELETE
A61K 39/464438		DELETE
A61K 39/464439		DELETE
A61K 39/46444		DELETE
A61K 39/464441		DELETE
A61K 39/464442		DELETE
A61K 39/464444		DELETE
A61K 39/464448		DELETE
A61K 39/464449		DELETE
A61K 39/46445		DELETE
A61K 39/464451		DELETE
A61K 39/464452		DELETE
A61K 39/464453		DELETE
A61K 39/464454		DELETE
A61K 39/464456		DELETE
A61K 39/464457		DELETE
A61K 39/464458		DELETE
A61K 39/464459		DELETE
A61K 39/46446		DELETE
A61K 39/464461		DELETE
A61K 39/464462		DELETE
A61K 39/464463		DELETE
A61K 39/464464		DELETE
A61K 39/464466		DELETE
A61K 39/464468		DELETE
A61K 39/464469		DELETE
A61K 39/46447		DELETE
A61K 39/464471		DELETE
A61K 39/464472		DELETE

CPC NOTICE OF CHANGES 1696

DATE: JANUARY 1, 2025

PROJECT RP12360

<u>CPC</u>	<u>IPC</u>	<u>Action*</u>
A61K 39/464473		DELETE
A61K 39/464474		DELETE
A61K 39/464476		DELETE
A61K 39/464478		DELETE
A61K 39/46448		DELETE
A61K 39/464481		DELETE
A61K 39/464482		DELETE
A61K 39/464484		DELETE
A61K 39/464486		DELETE
A61K 39/464488		DELETE
A61K 39/464489		DELETE
A61K 39/46449		DELETE
A61K 39/464491		DELETE
A61K 39/464492		DELETE
A61K 39/464493		DELETE
A61K 39/464494		DELETE
A61K 39/464495		DELETE
A61K 39/464496		DELETE
A61K 39/464497		DELETE
A61K 39/464498		DELETE
A61K 39/464499		DELETE
A61K 39/4645		DELETE
A61K 39/4646		DELETE
A61K 39/4647		DELETE
A61K 39/464711		DELETE
A61K 39/464712		DELETE
A61K 39/464713		DELETE
A61K 39/464714		DELETE
A61K 39/464715		DELETE
A61K 39/4648		DELETE
A61K 39/464811		DELETE
A61K 39/464812		DELETE
A61K 39/464813		DELETE
A61K 39/464814		DELETE
A61K 39/464815		DELETE
A61K 39/464816		DELETE
A61K 39/464817		DELETE
A61K 39/464818		DELETE
A61K 39/464819		DELETE
A61K 39/46482		DELETE
A61K 39/464821		DELETE
A61K 39/464822		DELETE
A61K 39/464823		DELETE
A61K 39/464824		DELETE
A61K 39/464825		DELETE

CPC NOTICE OF CHANGES 1696

DATE: JANUARY 1, 2025

PROJECT RP12360

CPC	IPC	Action*
A61K 39/464826		DELETE
A61K 39/464827		DELETE
A61K 39/464828		DELETE
A61K 39/464829		DELETE
A61K 39/46483		DELETE
A61K 39/464831		DELETE
A61K 39/464832		DELETE
A61K 39/464833		DELETE
A61K 39/464834		DELETE
A61K 39/464835		DELETE
A61K 39/464838		DELETE
A61K 39/464839		DELETE
A61K 39/46484		DELETE
A61K 40/00	A61K 40/00	NEW
A61K 40/10	A61K 40/10	NEW
A61K 40/11	A61K 40/11	NEW
A61K 40/13	A61K 40/13	NEW
A61K 40/15	A61K 40/15	NEW
A61K 40/17	A61K 40/17	NEW
A61K 40/19	A61K 40/19	NEW
A61K 40/20	A61K 40/20	NEW
A61K 40/22	A61K 40/22	NEW
A61K 40/24	A61K 40/24	NEW
A61K 40/30	A61K 40/30	NEW
A61K 40/31	A61K 40/31	NEW
A61K 40/32	A61K 40/32	NEW
A61K 40/33	A61K 40/33	NEW
A61K 40/34	A61K 40/34	NEW
A61K 40/35	A61K 40/35	NEW
A61K 40/36	A61K 40/36	NEW
A61K 40/40	A61K 40/40	NEW
A61K 40/405	A61K 40/40	NEW
A61K 40/41	A61K 40/41	NEW
A61K 40/412	A61K 40/41	NEW
A61K 40/414	A61K 40/41	NEW
A61K 40/416	A61K 40/41	NEW
A61K 40/418	A61K 40/41	NEW
A61K 40/42	A61K 40/42	NEW
A61K 40/4201	A61K 40/42	NEW
A61K 40/4202	A61K 40/42	NEW
A61K 40/4203	A61K 40/42	NEW
A61K 40/4204	A61K 40/42	NEW
A61K 40/4205	A61K 40/42	NEW
A61K 40/4206	A61K 40/42	NEW
A61K 40/4207	A61K 40/42	NEW

CPC NOTICE OF CHANGES 1696

DATE: JANUARY 1, 2025

PROJECT RP12360

<u>CPC</u>	<u>IPC</u>	<u>Action*</u>
A61K 40/4208	A61K 40/42	NEW
A61K 40/4209	A61K 40/42	NEW
A61K 40/421	A61K 40/42	NEW
A61K 40/4211	A61K 40/42	NEW
A61K 40/4212	A61K 40/42	NEW
A61K 40/4213	A61K 40/42	NEW
A61K 40/4214	A61K 40/42	NEW
A61K 40/4215	A61K 40/42	NEW
A61K 40/4216	A61K 40/42	NEW
A61K 40/4217	A61K 40/42	NEW
A61K 40/4218	A61K 40/42	NEW
A61K 40/4219	A61K 40/42	NEW
A61K 40/422	A61K 40/42	NEW
A61K 40/4221	A61K 40/42	NEW
A61K 40/4222	A61K 40/42	NEW
A61K 40/4223	A61K 40/42	NEW
A61K 40/4224	A61K 40/42	NEW
A61K 40/4225	A61K 40/42	NEW
A61K 40/4226	A61K 40/42	NEW
A61K 40/4227	A61K 40/42	NEW
A61K 40/4228	A61K 40/42	NEW
A61K 40/4229	A61K 40/42	NEW
A61K 40/423	A61K 40/42	NEW
A61K 40/4231	A61K 40/42	NEW
A61K 40/4232	A61K 40/42	NEW
A61K 40/4233	A61K 40/42	NEW
A61K 40/4234	A61K 40/42	NEW
A61K 40/4235	A61K 40/42	NEW
A61K 40/4236	A61K 40/42	NEW
A61K 40/4237	A61K 40/42	NEW
A61K 40/4238	A61K 40/42	NEW
A61K 40/4239	A61K 40/42	NEW
A61K 40/424	A61K 40/42	NEW
A61K 40/4241	A61K 40/42	NEW
A61K 40/4242	A61K 40/42	NEW
A61K 40/4243	A61K 40/42	NEW
A61K 40/4244	A61K 40/42	NEW
A61K 40/4245	A61K 40/42	NEW
A61K 40/4246	A61K 40/42	NEW
A61K 40/4247	A61K 40/42	NEW
A61K 40/4248	A61K 40/42	NEW
A61K 40/4249	A61K 40/42	NEW
A61K 40/425	A61K 40/42	NEW
A61K 40/4251	A61K 40/42	NEW
A61K 40/4252	A61K 40/42	NEW

CPC NOTICE OF CHANGES 1696

DATE: JANUARY 1, 2025

PROJECT RP12360

<u>CPC</u>	<u>IPC</u>	<u>Action*</u>
A61K 40/4253	A61K 40/42	NEW
A61K 40/4254	A61K 40/42	NEW
A61K 40/4255	A61K 40/42	NEW
A61K 40/4256	A61K 40/42	NEW
A61K 40/4257	A61K 40/42	NEW
A61K 40/4258	A61K 40/42	NEW
A61K 40/4259	A61K 40/42	NEW
A61K 40/426	A61K 40/42	NEW
A61K 40/4261	A61K 40/42	NEW
A61K 40/4262	A61K 40/42	NEW
A61K 40/4263	A61K 40/42	NEW
A61K 40/4264	A61K 40/42	NEW
A61K 40/4265	A61K 40/42	NEW
A61K 40/4266	A61K 40/42	NEW
A61K 40/4267	A61K 40/42	NEW
A61K 40/4268	A61K 40/42	NEW
A61K 40/4269	A61K 40/42	NEW
A61K 40/427	A61K 40/42	NEW
A61K 40/4271	A61K 40/42	NEW
A61K 40/4272	A61K 40/42	NEW
A61K 40/4273	A61K 40/42	NEW
A61K 40/4274	A61K 40/42	NEW
A61K 40/4275	A61K 40/42	NEW
A61K 40/4276	A61K 40/42	NEW
A61K 40/4277	A61K 40/42	NEW
A61K 40/4278	A61K 40/42	NEW
A61K 40/4279	A61K 40/42	NEW
A61K 40/428	A61K 40/42	NEW
A61K 40/4285	A61K 40/41	NEW
A61K 40/429	A61K 40/40	NEW
A61K 40/43	A61K 40/43	NEW
A61K 40/432	A61K 40/43	NEW
A61K 40/434	A61K 40/43	NEW
A61K 40/436	A61K 40/43	NEW
A61K 40/438	A61K 40/43	NEW
A61K 40/4385	A61K 40/43	NEW
A61K 40/44	A61K 40/44	NEW
A61K 40/45	A61K 40/45	NEW
A61K 40/4512	A61K 40/45	NEW
A61K 40/4514	A61K 40/45	NEW
A61K 40/4516	A61K 40/45	NEW
A61K 40/4518	A61K 40/45	NEW
A61K 40/452	A61K 40/45	NEW
A61K 40/4522	A61K 40/45	NEW
A61K 40/4524	A61K 40/45	NEW

CPC NOTICE OF CHANGES 1696

DATE: JANUARY 1, 2025

PROJECT RP12360

<u>CPC</u>	<u>IPC</u>	<u>Action*</u>
A61K 40/4526	A61K 40/45	NEW
A61K 40/4528	A61K 40/45	NEW
A61K 40/453	A61K 40/45	NEW
A61K 40/4532	A61K 40/45	NEW
A61K 40/4534	A61K 40/45	NEW
A61K 40/4536	A61K 40/45	NEW
A61K 40/4538	A61K 40/45	NEW
A61K 40/454	A61K 40/45	NEW
A61K 40/4542	A61K 40/45	NEW
A61K 40/4544	A61K 40/45	NEW
A61K 40/4546	A61K 40/45	NEW
A61K 40/4548	A61K 40/45	NEW
A61K 40/455	A61K 40/45	NEW
A61K 40/456	A61K 40/45	NEW
A61K 40/4562	A61K 40/45	NEW
A61K 40/4564	A61K 40/45	NEW
A61K 40/4566	A61K 40/45	NEW
A61K 40/4568	A61K 40/45	NEW
A61K 40/46	A61K 40/46	NEW
A61K 40/48	A61K 40/48	NEW
A61K 40/482	A61K 40/48	NEW
A61K 40/50	A61K 40/50	NEW
A61K 2239/26		DELETE

* Action column:

- For an (N) or (Q) entry, provide an IPC symbol and complete the Action column with “NEW.”
- For an existing CPC main trunk entry or indexing entry where the existing IPC symbol needs to be changed, provide an updated IPC symbol and complete the Action column with “UPDATED.”
- For a (D) CPC entry or indexing entry complete the Action column with “DELETE.” IPC symbol does not need to be included in the IPC column.
- For an (N) 2000 series CPC entry which is positioned within the main trunk scheme (breakdown code) provide an IPC symbol and complete the action column with “NEW”.
- For an (N) 2000 series CPC entry positioned at the end of the CPC scheme (orthogonal code), with no IPC equivalent, complete the IPC column with “CPCONLY” and complete the action column with “NEW”.

NOTES:

- F symbols are not included in the CICL table above.
- T and M symbols are not included in the CICL table above unless a change to the existing IPC is desired.

CPC NOTICE OF CHANGES 1696

DATE: JANUARY 1, 2025

PROJECT RP12360

5. CROSS-REFERENCE LIST (CRL)

Scheme references impacted by this revision project

<u>Location of reference to be changed</u>	<u>Referenced subclass or group to be changed</u>	<u>Action; New reference symbol; New text</u>
A61K2239/00	A61K39/46	Replace with A61K40/00

Definitions references impacted by this revision project

<u>Location of reference to be changed</u>	<u>Referenced subclass or group to be changed</u>	<u>Section of definition</u>	<u>Action; New reference symbol; New text</u>
C12N5/00	A61K39/46- A61K39/46484	Definition statement	Replace with: A61K40/00 - A61K40/50
C12N5/00	A61K39/46	Special rules of classification	Replace with: A61K40/00

NOTES:

- The CRL tables above are used for changes to locations **outside** of the project scope. Changes to references in scheme titles or definitions **inside** the project scope will be reflected in the “scheme change” template or one of the “definition” templates.
- In addition to other changes proposed in the tables above, in the column titled “Referenced subclass or group to be changed,” **referenced** D symbols should indicate an action of “delete” or should indicate a replacement symbol and **referenced** F symbols should indicate a replacement symbol.
- When a reference is deleted, text related to that reference will also be deleted unless other references or a range of references associated with the same text remain.